Literature DB >> 26559436

Antiviral treatment for Bell's palsy (idiopathic facial paralysis).

Ildiko Gagyor1, Vishnu B Madhok, Fergus Daly, Dhruvashree Somasundara, Michael Sullivan, Fiona Gammie, Frank Sullivan.   

Abstract

BACKGROUND: Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. Significant morbidity can be associated with severe cases of Bell's palsy. This review was first published in 2001 and revised several times, most recently in 2009. This version replaces an update of the review in Issue 7 of the Cochrane Library subsequently withdrawn because of an ongoing investigation into the reliability of data from an included study.
OBJECTIVES: To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy. SEARCH
METHODS: On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, DARE, NHS EED, and HTA. We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies. SELECTION CRITERIA: We considered randomised controlled trials or quasi-randomised controlled trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that had a high risk of bias in several domains. DATA COLLECTION AND ANALYSIS: Pairs of authors independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures. MAIN
RESULTS: Ten trials, including 2280 participants, met the inclusion criteria and are included in the final analysis. Some of the trials were small, and a number were at high or unclear risk of bias. Other trials did not meet current best standards in allocation concealment and blinding. Incomplete recoveryWe found a significant benefit from adding antivirals to corticosteroids in comparison with corticosteroids alone for people with Bell's palsy (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.39 to 0.97, n = 1315). For people with severe Bell's palsy (House-Brackmann scores of 5 and 6 or the equivalent in other scales), we found a reduction in the rate of incomplete recovery at month six when antivirals plus corticosteroids were used, compared to corticosteroids alone (RR 0.64, 95% CI 0.41 to 0.99, n = 478). The outcome for the participants receiving corticosteroids alone was significantly better than for those receiving antivirals alone (RR 2.82, 95% CI 1.09 to 7.32, n = 768). The treatment effect of placebo was significantly lower than that of antivirals plus corticosteroids (RR 0.56, 95% CI 0.41 to 0.76, n = 658). Antivirals alone produced no benefit compared with placebo (RR 1.10, 95% CI 0.87 to 1.40, n = 658). Motor synkinesis or crocodile tearsIn two trials comparing antivirals and corticosteroids with corticosteroids and placebo that assessed this outcome, we found a significant difference in long-term sequelae in favour of antivirals plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87, n = 469). Two trials comparing antivirals alone with corticosteroids alone investigating this outcome showed fewer sequelae with corticosteroids (RR 1.52, 95% CI 1.08 to 2.12, n = 472). We found no data on long-term sequelae for other comparisons. Adverse events Adverse event data were available in three studies giving comparison data on 1528 participants. None of the four comparisons (antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment; antivirals versus corticosteroids; antivirals plus corticosteroids versus placebo; antivirals versus placebo) showed significant differences in adverse events between treatment and control arms. We could find no correlation with specific treatment within these results. AUTHORS'
CONCLUSIONS: Low-quality evidence from randomised controlled trials showed a benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone for the treatment of Bell's palsy of various degrees of severity. Low-quality evidence showed a benefit of combination therapy compared with corticosteroids alone in severe Bell's palsy. Corticosteroids alone were more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no benefit from antivirals alone over placebo.Moderate-quality evidence indicated that the combination of antivirals and corticosteroids reduced sequelae of Bell's palsy compared with corticosteroids alone.We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids, based on low-quality evidence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26559436     DOI: 10.1002/14651858.CD001869.pub8

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  13 in total

1.  Comparison of acyclovir and famciclovir for the treatment of Bell's palsy.

Authors:  Ho Joong Kim; Sang Hoon Kim; Junyang Jung; Sung Su Kim; Jae Yong Byun; Moon Suh Park; Seung Geun Yeo
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-12       Impact factor: 2.503

2.  A young woman with acute one-sided facial paralysis.

Authors:  Ildikó Gagyor; Vishnu Madhok; Frank Sullivan
Journal:  CMAJ       Date:  2016-09-12       Impact factor: 8.262

Review 3.  Herpes Zoster in the Older Adult.

Authors:  Amrita R John; David H Canaday
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

Review 4.  Corticosteroids for Bell's palsy (idiopathic facial paralysis).

Authors:  Vishnu B Madhok; Ildiko Gagyor; Fergus Daly; Dhruvashree Somasundara; Michael Sullivan; Fiona Gammie; Frank Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

5.  Infections in the differential diagnosis of Bell's palsy: a plea for performing CSF analysis.

Authors:  Katrin Henkel; Peter Lange; Helmut Eiffert; Roland Nau; Annette Spreer
Journal:  Infection       Date:  2016-08-16       Impact factor: 7.455

Review 6.  Management of Bell's palsy.

Authors:  Dhruvashree Somasundara; Frank Sullivan
Journal:  Aust Prescr       Date:  2017-06-01

7.  Antiviral treatment for Bell's palsy (idiopathic facial paralysis).

Authors:  Ildiko Gagyor; Vishnu B Madhok; Fergus Daly; Frank Sullivan
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05

8.  Recurrent Bell's palsy: outcomes and correlation with clinical comorbidities.

Authors:  P Mancini; V Bottaro; F Capitani; G De Soccio; L Prosperini; P Restaino; M De Vincentiis; A Greco; G A Bertoli; D De Seta
Journal:  Acta Otorhinolaryngol Ital       Date:  2019-10       Impact factor: 2.124

9.  Guillain-Barré Syndrome: A Variant Consisting of Facial Diplegia and Paresthesia with Left Facial Hemiplegia Associated with Antibodies to Galactocerebroside and Phosphatidic Acid.

Authors:  Sho Nishiguchi; Joel Branch; Tsubasa Tsuchiya; Ryoji Ito; Junya Kawada
Journal:  Am J Case Rep       Date:  2017-10-02

10.  The Binary Classification Of Chronic Diseases.

Authors:  Zeev Elkoshi
Journal:  J Inflamm Res       Date:  2019-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.